Mitoxantrone liposome + Cytarabine + Azacitidine

The combination of mitoxantrone liposome (also known as liposomal mitoxantrone or Lipo-MIT), cytarabine, and azacitidine represents a therapeutic regimen being investigated primarily for acute myeloid leukemia (AML), particularly in relapsed/refractory cases. This combination leverages the epigenetic priming effect of azacitidine (a hypomethylating agent) followed by the cytotoxic effects of liposomal mitoxantrone and cytarabine. ## Mechanism and Clinical Development Mitoxantrone liposome is a nano-drug formulation of mitoxantrone, a synthetic anthracenedione anticancer agent that intercalates into DNA, causes crosslinks and strand breaks, and inhibits topoisomerase II[1][9]. The liposomal formulation improves pharmacokinetics and potentially reduces toxicity compared to conventional mitoxantrone[6][10]. In this combination: - Azacitidine acts as an epigenetic primer by hypomethylating DNA - Cytarabine (HiDAC - high-dose cytarabine) is a cytotoxic agent that interferes with DNA synthesis - Liposomal mitoxantrone intercalates into DNA and inhibits topoisomerase II A phase 1 study demonstrated that azacitidine (at doses up to 75 mg/m² daily for 5 days) followed by high-dose cytarabine and mitoxantrone was safe and effective in high-risk AML patients[1][2]. The recommended phase 2 dose established was azacitidine 75 mg/m² per day on days 1-5 followed by cytarabine (3000 mg/m²) and mitoxantrone (30 mg/m²) once each on days 6 and 10[1][2]. The overall response rate in this study was 61%, with particularly good responses observed in previously untreated patients aged ≥60 years with therapy-related AML and de novo AML, as well as those with NPM1 or IDH2 mutations[1][2]. ## Safety Profile The combination therapy has shown manageable toxicity. In the phase 1 study with conventional mitoxantrone, the 30-day induction death rate was only 2.2%[1][2]. Dose-limiting toxicities included acute liver failure and kidney injury, observed in one patient at the 50 mg/m² dose of azacitidine[1][2]. The liposomal formulation of mitoxantrone may offer advantages in terms of reduced cardiotoxicity compared to conventional mitoxantrone, as suggested by studies of liposomal mitoxantrone in other indications[6][10]. This combination represents a promising approach for treating high-risk AML, particularly as a bridge to hematopoietic stem cell transplantation in relapsed/refractory cases.